IO Biotech, Inc. (IOBT) NASDAQ
0.01
-0.00469(-27.59%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.01
-0.00469(-27.59%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
80
First IPO Date
November 05, 2021
| Name | Title | Pay | Year Born |
| Mai-Britt Zocca | Founder, President, Chief Executive Officer, Principal Financial Officer & Director | 908,461 | 1968 |
| Devin Whittemore Smith | Secretary, General Counsel & Chief Compliance Officer | 621,800 | 1968 |
| Amy Sullivan | Principal Accounting Officer & CFO | 650,708 | 1970 |
| Qasim Iftikhar Ahmad | Chief Medical Officer | 709,800 | 1972 |
| Marjan Shamsaei | Senior Vice President of Commercial Development & Portfolio Lead | 0 | N/A |
| Per Thor Straten | Founder | 0 | N/A |
| Daniel G. Mannix | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Eric Faulkner | Chief Technical Officer | 0 | N/A |
| Inge Marie Svane | Founder & Clinical Advisor | 0 | N/A |
| Mads Hald Andersen | Co-Founder & Scientific Advisor | 0 | N/A |
| Anders Ljungqvist | Founder | 0 | N/A |
| Faical Miyara | Chief Business Officer | 0 | N/A |
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.